EVOK - Evoke Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.74
+0.01 (+0.37%)
As of 9:43AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close2.73
Open2.75
Bid2.72 x 1000
Ask2.76 x 1000
Day's Range2.74 - 2.75
52 Week Range1.85 - 4.09
Volume391
Avg. Volume90,435
Market Cap45.963M
Beta3.29
PE Ratio (TTM)N/A
EPS (TTM)-0.68
Earnings DateMay 14, 2018 - May 18, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.80
Trade prices are not sourced from all markets
  • At $2.8701, Is Evoke Pharma Inc (NASDAQ:EVOK) A Buy?
    Simply Wall St.14 days ago

    At $2.8701, Is Evoke Pharma Inc (NASDAQ:EVOK) A Buy?

    Evoke Pharma Inc (NASDAQ:EVOK), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM over the last few months. WithRead More...

  • GlobeNewswire16 days ago

    Evoke Announces FDA Submission of New Drug Application for Gimoti™

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the submission of its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Gimoti™, the Company’s nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. “Our NDA submission for Gimoti represents a significant step forward for Evoke and Gimoti, which has the potential to meaningfully improve the lives of patients who suffer from the devastating symptoms of gastroparesis,” commented Dave Gonyer, President and CEO. Existing oral treatment options may be ineffective during an acute flare, which we believe creates the need for a nonoral treatment option.

  • Evoke Pharma Inc (NASDAQ:EVOK) Is Expected To Breakeven
    Simply Wall St.last month

    Evoke Pharma Inc (NASDAQ:EVOK) Is Expected To Breakeven

    Evoke Pharma Inc’s (NASDAQ:EVOK): Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. On 31 December 2017,Read More...

  • GlobeNewswirelast month

    Evoke Pharma Reports First Quarter 2018 Results and Highlights

    NDA submission for Gimoti™ on track for second quarter of 2018 Announced discovery of sex-based pharmacokinetic differences for Gimoti Waiver of the PDUFA fee for Gimoti NDA granted by FDA Cash runway ...

  • GlobeNewswirelast month

    Evoke Granted Gender Specific Patent for Gimoti™ in Mexico

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Mexican Institute of Industrial Property has issued a Notice that it intends to grant Mexican Patent Application MX/a/2014/002125 for Gimoti, covering uses of metoclopramide for intranasal delivery for the treatment of symptoms associated with diabetic gastroparesis specifically for women. “This is the second allowance from our estate of international patent applications directed toward female specific intellectual property in gastroparesis,” commented Dave Gonyer, President and CEO. “The studies we have conducted have shown significant differences in how to treat patients with gastroparesis.

  • GlobeNewswire2 months ago

    Evoke Granted First Gender Specific Patent for Gimoti™

    Evoke Pharma, Inc. (EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that the European Patent Office has issued a Decision to Grant European Union (EU) patent no. 2747561 for Gimoti™, covering formulations of metoclopramide for intranasal delivery for the treatment of symptoms associated with diabetic gastroparesis specifically for women. The notice confirms that the patent grant applies to 38 covered member states and will be published on May 9, 2018 with patent expiry extended to 2032. “This patent represents the first female specific intellectual property approved for Gimoti and highlights the significant work we’ve accomplished in developing this novel new treatment for gastroparesis,” commented Dave Gonyer, President and CEO.

  • GlobeNewswire3 months ago

    Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments

    SOLANA BEACH, Calif., March 26, 2018-- Evoke Pharma, Inc., a specialty pharmaceutical company focused on treatments for gastrointestinal d­­ iseases, today announced that it has amended the Company’ s ...

  • ACCESSWIRE3 months ago

    Evoke Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Evoke Pharma, Inc. (NASDAQ: EVOK ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 7, 2018 at 4:30 PM Eastern Time. To ...

  • ACCESSWIRE6 months ago

    Wired News – Akari’s Phase-II COBALT Trial of Coversin in Patients with PNH Met the Primary Endpoint

    Stock Monitor: Evoke Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 12, 2017 / Active-Investors issued a free report on Akari Therapeutics, PLC (NASDAQ: AKTX ), which is readily accessible ...

  • ACCESSWIRE6 months ago

    Wired News – SteadyMed Reported FDA Agreed Pathway to Trevyent NDA Resubmission

    Stock Monitor: Evoke Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 11, 2017 / Active-Investors issued a free report on SteadyMed Ltd (NASDAQ: STDY ), which is readily accessible upon ...

  • ACCESSWIRE7 months ago

    Evoke Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 14, 2017 / Evoke Pharma, Inc. (EXCHANGE: EVOK ) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, 2017 at 4:30 ...

  • A Look At Evoke Pharma Inc (EVOK) And The Healthcare Sector
    Simply Wall St.7 months ago

    A Look At Evoke Pharma Inc (EVOK) And The Healthcare Sector

    Evoke Pharma Inc (NASDAQ:EVOK), a USD$43.09M small-cap, is a healthcare company operating in an industry, which continues to endure a more demanding healthcare agenda, and the global need for innovative,Read More...